News coverage about RadNet (NASDAQ:RDNT) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. RadNet earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.3823266298813 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
RDNT has been the topic of a number of recent analyst reports. Jefferies Group LLC upgraded RadNet from a “hold” rating to a “buy” rating and increased their price target for the stock from $7.00 to $12.00 in a research report on Tuesday, August 22nd. BidaskClub upgraded RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, TheStreet upgraded RadNet from a “c” rating to a “b-” rating in a research report on Thursday, August 24th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $9.63.
Shares of RadNet (RDNT) traded down 0.673% during trading on Monday, reaching $11.075. The company’s stock had a trading volume of 147,961 shares. RadNet has a 52 week low of $5.25 and a 52 week high of $11.50. The firm has a market capitalization of $523.47 million, a P/E ratio of 58.289 and a beta of 0.92. The company has a 50 day moving average price of $9.30 and a 200 day moving average price of $7.36.
RadNet (NASDAQ:RDNT) last released its earnings results on Tuesday, August 8th. The medical research company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.07. RadNet had a return on equity of 19.98% and a net margin of 1.04%. The company had revenue of $230.00 million for the quarter, compared to analysts’ expectations of $230.32 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts expect that RadNet will post $0.30 EPS for the current fiscal year.
In other RadNet news, insider Norman R. Hames sold 8,074 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $7.60, for a total transaction of $61,362.40. Following the transaction, the insider now owns 413,157 shares in the company, valued at approximately $3,139,993.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael L. Md Sherman sold 8,035 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $11.02, for a total value of $88,545.70. Following the transaction, the director now owns 301,957 shares in the company, valued at approximately $3,327,566.14. The disclosure for this sale can be found here. Insiders have sold a total of 111,782 shares of company stock worth $1,106,003 in the last quarter. 9.36% of the stock is currently owned by insiders.
RadNet Company Profile
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.